COVID-19: Healthcare Stakeholders Analysis in the USA and EU-5

A Healthcare Stakeholders Analysis in the United States and EU-5 and a Practical Guide for Product Suppliers

The COVID-19 pandemic is having a disruptive effect on every corner of the healthcare industry, but its impact on individual stakeholders varies widely. Differences in exposure to COVID-19 patients, the relevance of product portfolios to the disease, and the level of preparedness for a pandemic have forced many across the industry to re-evaluate their strategies, quickly pivot to support urgent needs, and work to strengthen their position for the long-term rebound.

Alira Health’s team of strategists, scientists, doctors, and bankers continue to monitor the key trends and will share their perspective on underlying short, medium and long term implications to support the industry through this crisis and help continue to move healthcare forward during this time of uncertainty.

This 20-page report includes comprehensive analyses of the COVID-19 impact as of April 14, including:

• An up-to-date digest of the impact COVID-19 is having on key healthcare stakeholders
• Analysis of key trends and anticipated emerging needs
• Business approaches for short-term reaction, and business model adaptations to help optimize for the rebound

For more information please contact our team:

• Piergiulio Lauriano, Partner
• Aude Ouensanga, Partner
• Deepak Sahu, Partner
• Christopher Rao, Vice President, Clinical Development

Alira Health makes no representations or warranties, either expressed or implied, as to the accuracy of the information in this report. Alira Health has collected and compiled the presented information on a best effort basis under time and budget constraints. In no event will Alira Health be held liable for any direct, indirect, incidental or consequential damages arising out of the use of the information in this report.

Unless otherwise explicitly stated, all information is copyrighted by Alira Health, irrespective of whether a copyright symbol and statement is present. All trademarks are acknowledged.